Why Sermorelin Is Different From Other GH Peptides
Sermorelin was FDA-approved in 1997 under the brand name Geref. It was withdrawn from the market in 2008 for commercial reasons — not safety reasons — making it one of the few peptides in the longevity space with genuine human clinical data from the FDA approval process. This history informs how physicians approach dosing and monitoring.
How a Sermorelin Protocol Works
Sermorelin is typically administered by subcutaneous injection, most commonly at bedtime to align with the body’s natural nighttime GH pulse. The physician sets the dose based on age, weight, clinical goals, and baseline IGF-1 levels. Lab work before and during the protocol allows objective measurement of response.
Protocol Duration and Monitoring
Sermorelin protocols typically run 3-6 months minimum, with IGF-1 monitoring at 90 days to assess response. Unlike direct GH administration, Sermorelin works through the body’s own feedback systems, making it more physiologically regulated. Physicians adjust dose based on lab results, not subjective response alone.
Accessing Sermorelin Through Telehealth
Sermorelin is currently available through licensed 503A compounding pharmacies with a physician prescription. A telehealth consultation eliminates the need for in-person clinic visits and allows nationwide access regardless of location.